XNCR Stock Analysis: Xencor | NASDAQ

Oncology, Autoimmune, Bispecific Antibodies, Antibody Engineering

Total Rating 51

Safety 72

Buy Signal 0.96

Biotechnology
Industry Rotation: +10.0

Market Cap: 2.01B
Avg Turnover: 24.6M

Risk 3d forecast

Volatility64.4%

VaR 5^th Pctl10.2%

VaR vs Median-3.50%

Reward TTM

Sharpe Ratio2.24

Rel. Str. IBD99

Rel. Str. Peer Group88.3

Character TTM

Beta0.938

Beta Downside0.535

Hurst Exponent0.360

Drawdowns 3y

Max DD73.92%

CAGR/Max DD0.12

CAGR/Mean DD0.25

EPS (Earnings per Share)

Last SUE: 1.03
Qual. Beats: 1

Revenue

Rev. CAGR: -11.42%
Rev. Trend: -52.0%

Last SUE: 1.51
Qual. Beats: 1

Warnings

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Fakeout

Tailwinds

Supp Ema8

Rs Leader

Idiosyncratic Leader

Tailwind

Pullback 52w

Seasonality 11.6 years of data

Jan -5.8% 23

Feb -0.2% 7

Mar -6.7% 36

Apr -0.5% 15

May +1.1% 17

Jun +4.6% 18

Jul +6.7% 24

Aug -0.6% 15

Sep +4.5% 15

Oct -0.2% 0

Nov +12.9% 68

Dec -4.8% 27

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: XNCR Xencor

Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharmaceutical company headquartered in Pasadena, California, founded in 1997. The company focuses on the discovery and development of engineered antibody therapeutics for the treatment of cancer and autoimmune diseases, and is classified in the GICS Health Care / Biotechnology sub-industry with a small-cap market capitalization of approximately $937 million.

The companys pipeline is broad and diversified, spanning multiple antibody formats including bispecific T-cell engagers, bispecific antibodies targeting tumor antigens, and Fc-engineered antibodies. Clinical candidates target a range of indications such as renal cell carcinoma, ovarian cancer, prostate cancer, B-cell malignancies, Crohns disease, ulcerative colitis, rheumatoid arthritis, and idiopathic inflammatory myopathies. Several programs are being advanced in collaboration with larger pharmaceutical partners including Novartis, Johnson & Johnson, and Astellas, indicating a partnership-driven development model that helps share clinical risk and funding obligations.

As a clinical-stage biotech, Xencor has not yet established a self-sustaining commercial revenue base from its own approved products. Companies in this segment typically rely on a combination of out-licensed royalties, milestone payments from collaborators, and periodic capital markets financing to fund ongoing research and clinical trials, with revenue often lumpy and dependent on partnership events rather than recurring product sales.

Headlines to Watch Out For

Obexelimab and Xaluritamig Phase II data readouts approach
Novartis J&J Astellas partnerships generate milestone payments
Cash runway remains tight amid rising clinical-stage R&D burn

Piotroski VR-10 (Strict) 1.0

Net Income: -163.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.03 > 0.02 and ΔFCF/TA 11.34 > 1.0
NWC/Revenue: 420.4% < 20% (prev 254.1%; Δ 166.4% < -1%)
CFO/TA -0.28 > 3% & CFO -205.8m > Net Income -163.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.39 > 1.5 & < 3
Outstanding Shares: last quarter (75.9m) vs 12m ago 2.13% < -2%
Gross Margin: 89.99% > 18% (prev 30.17%; Δ 59.82% > 0.5%)
Asset Turnover: 13.09% > 50% (prev 18.67%; Δ -5.58% > 0%)
Interest Coverage Ratio: -4.94 > 6 (EBIT TTM -133.8m / Interest Expense TTM 27.1m)

Altman Z'' 1.00

A: 0.61 (Total Current Assets 523.2m - Total Current Liabilities 81.9m) / Total Assets 725.0m
B: -1.31 (Retained Earnings -946.6m / Total Assets 725.0m)
C: -0.17 (EBIT TTM -133.8m / Avg Total Assets 802.2m)
D: 2.27 (Book Value of Equity 503.2m / Total Liabilities 221.7m)
Altman-Z'' = 1.00 = BB

Beneish M -3.85

DSRI: 1.39 (Receivables 42.2m/47.6m, Revenue 105.0m/164.2m)
GMI: 0.34 (GM 30.17% / 89.99%)
AQI: 0.52 (AQ_t 0.16 / AQ_t-1 0.31)
SGI: 0.64 (Revenue 105.0m / 164.2m)
TATA: 0.06 (NI -163.3m - CFO -205.8m) / TA 725.0m)
Beneish M = -3.85 (Cap -4..+1) = AAA

What is the price of XNCR shares?

As of August 26, 2026, the stock is trading at USD 29.30 with a total of 1,566,748 shares traded. Over the past week, the price has changed by +15.31%, over one month by +47.53%, over three months by +151.93% and over the past year by +265.79%.

Current recommended Stop Loss: 27.50 (which is 6.1% or 1.3 ATR below the current price).

Is XNCR a buy, sell or hold?

Xencor has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy XNCR.

StrongBuy: 8
Buy: 3
Hold: 0
Sell: 1
StrongSell: 0

What are the forecasts/targets for the XNCR price?

Analysts Target Price	29	-1%

Xencor (XNCR) - Fundamental Data Overview as of 22 August 2026

Market Cap USD = 2.01b (2.01b USD * 1.0 USD.USD)
P/E Forward = 68.0272
P/S = 19.1244
P/B = 4.0676
Revenue TTM = 105.0m USD
EBIT TTM = -133.8m USD
EBITDA TTM = -123.6m USD
Long Term Debt = 77.5m USD (from longTermDebt, last quarter)
Short Term Debt = 3.92m USD (from shortTermDebt, last quarter)
Debt = 146.7m USD (corrected: LT Debt 77.5m + ST Debt 3.92m) + Leases 65.2m
Net Debt = -309.8m USD (calculated: Debt 146.7m - CCE 456.5m)
Enterprise Value = 1.70b USD (2.01b + Debt 146.7m - CCE 456.5m)
Interest Coverage Ratio = -4.94 (Ebit TTM -133.8m / Interest Expense TTM 27.1m)
EV/FCF = -69.42x (Enterprise Value 1.70b / FCF TTM -24.5m)
FCF Yield = -1.44% (FCF TTM -24.5m / Enterprise Value 1.70b)
FCF Margin = -23.30% (FCF TTM -24.5m / Revenue TTM 105.0m)
Net Margin = -155.6% (Net Income TTM -163.3m / Revenue TTM 105.0m)
Gross Margin = 89.99% ((Revenue TTM 105.0m - Cost of Revenue TTM 10.5m) / Revenue TTM)
Gross Margin QoQ = none% (prev 43.16%)
Tobins Q-Ratio = 2.34 (Enterprise Value 1.70b / Total Assets 725.0m)
Interest Expense / Debt = 18.46% (Interest Expense 27.1m / Debt 146.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -105.7m (EBIT -133.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.54 (Total Current Assets 523.2m / Total Current Liabilities 94.5m)
Debt / Equity = 0.29 (Debt 146.7m / totalStockholderEquity, last quarter 503.2m)
Debt / EBITDA = 2.51 (negative EBITDA) (Net Debt -309.8m / EBITDA -123.6m)
Debt / FCF = 12.67 (negative FCF - burning cash) (Net Debt -309.8m / FCF TTM -24.5m)
Total Stockholder Equity = 569.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.36% (Net Income -163.3m / Total Assets 725.0m)
RoE = -28.66% (Net Income TTM -163.3m / Total Stockholder Equity 569.9m)
RoCE = -20.66% (EBIT -133.8m / Capital Employed (Equity 569.9m + L.T.Debt 77.5m))
RoIC = -16.47% (negative operating profit) (NOPAT -105.7m / Invested Capital 641.8m)
WACC = 9.63% (E(2.01b)/V(2.15b) * Re(9.27%) + D(146.7m)/V(2.15b) * Rd(18.46%) * (1-Tc(0.21)))
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.21 | Cagr: 10.00%
[DCF] Fair Price = unknown (Cash Flow -24.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.03 | # QB: 1
Revenue Correlation: -52.04 | Revenue CAGR: -11.42% | SUE: 1.51 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-0.32 | Chg30d=+61.27% | Revisions=+62% | Analysts=11
EPS current Year (2026-12-31): EPS=-3.11 | Chg30d=+22.66% | Revisions=+67% | GrowthEPS=-151.1% | GrowthRev=+14.6%
EPS next Year (2027-12-31): EPS=-3.49 | Chg30d=+1.67% | Revisions=-22% | GrowthEPS=-12.0% | GrowthRev=-12.7%
[Analyst] Revisions Ratio: +45% (up=13, down=4)